Bachem Holding AG (SWX:BANB)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 6.19B +50.3% |
| Revenue (ttm) | 708.53M +4.5% |
| Net Income | 148.96M +11.0% |
| EPS | 1.98 +10.4% |
| Shares Out | 74.94M |
| PE Ratio | 41.61 |
| Forward PE | 30.64 |
| Dividend | 0.90 (1.09%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 112,022 |
| Open | 83.75 |
| Previous Close | 84.15 |
| Day's Range | 81.70 - 84.60 |
| 52-Week Range | 48.52 - 86.00 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 84.30 (+2.12%) |
| Earnings Date | Mar 4, 2027 |
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, an... [Read more]
Financial Performance
In 2025, Bachem Holding AG's revenue was 695.07 million, an increase of 14.84% compared to the previous year's 605.26 million. Earnings were 148.79 million, an increase of 23.74%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for BANB stock is "Buy." The 12-month stock price target is CHF 84.30, which is an increase of 2.12% from the latest price.
News
Bachem price target raised to CHF 90 from CHF 85 at JPMorgan
JPMorgan analyst Zain Ebrahim raised the firm’s price target on Bachem (BCHMF) to CHF 90 from CHF 85 and keeps an Overweight rating on the shares.
Bachem Holding AG Annual report
Bachem Holding AG has published an annual report on September 4, 2026.
Bachem Holding AG Earnings Call Transcript: H1 2026
H1 2026 sales grew 4% (7.3% in local currency) to CHF 326.4 million, driven by CMC Development, while Commercial API sales declined but are expected to rebound in H2. Full-year sales growth is guided at 35%-40% with EBITDA margin in the low 30s, supported by major capacity expansions and strong market demand.
Bachem Holding AG Quarterly report: H1 2026
Bachem Holding AG has published its H1 2026 quarterly earnings report on July 30, 2026.
Bachem Holding AG Slides: H1 2026
Bachem Holding AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
Bachem Holding AG Earnings release: H1 2026
Bachem Holding AG released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
Bachem Holding AG Announces Capital Markets Day 2026
Join us in Zurich on 26 November 2026 Bubendorf, Switzerland--(Newsfile Corp. - June 12, 2026) - Bachem Holding AG (SIX: BANB) will host its Capital Markets Day on 26 November 2026 at The Circle Conve...
Bachem price target raised to CHF 65 from CHF 60 at Barclays
Barclays raised the firm’s price target on Bachem (BCHMF) to CHF 65 from CHF 60 and keeps an Equal Weight rating on the shares.
Bachem price target raised to CHF 80 from CHF 75 at Deutsche Bank
Deutsche Bank analyst Fynn Scherzler raised the firm’s price target on Bachem (BCHMF) to CHF 80 from CHF 75 and keeps a Buy rating on the shares. Published first on…
Bachem Holding AG Earnings Call Transcript: H2 2025
Sales grew 14.8% to CHF 695.1 million in 2025, with EBITDA margin at 30.9% and strong CapEx for expansion. 2026 guidance targets 35%-45% sales growth and low 30s% EBITDA margin, driven by Building K ramp-up and robust demand for complex peptides and oligonucleotides.
Bachem Holding AG Annual report: H2 2025
Bachem Holding AG has published its H2 2025 annual report on March 12, 2026.
Bachem Holding AG Earnings release: H2 2025
Bachem Holding AG released its H2 2025 earnings on March 12, 2026, summarizing the period's financial results.
Bachem Holding AG Slides: H2 2025
Bachem Holding AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 12, 2026.
Bachem price target raised to CHF 110 from CHF 78 at RBC Capital
RBC Capital raised the firm’s price target on Bachem (BCHMF) to CHF 110 from CHF 78 and keeps an Outperform rating on the shares.
Bachem price target lowered to CHF 60 from CHF 75 at Barclays
Barclays lowered the firm’s price target on Bachem (BCHMF) to CHF 60 from CHF 75 and keeps an Equal Weight rating on the shares.
Bachem upgraded to Buy from Neutral at UBS
UBS upgraded Bachem (BCHMF) to Buy from Neutral with a price target of CHF 78, up from CHF 76. The firm views the recent share selloff as a buying opportunity.